MB49 Syngeneic Model Overview
The MB49 syngeneic model is a murine urothelial carcinoma (bladder cancer) system derived from C57BL/6 mice and is one of the most widely used preclinical models for studying bladder cancer in an immunocompetent setting. This model reproduces key pathological and immunological features of human urothelial carcinoma, including immune evasion, local invasion, and responsiveness to immunotherapy.
When implanted subcutaneously, intravesically, or intraperitoneally, MB49 cells form highly reproducible tumors with well-characterized growth kinetics. The intravesical implantation route, in particular, enables the development of orthotopic bladder tumors that closely mimic the clinical course of human disease. The MB49 system is routinely used for evaluating immune checkpoint inhibitors, cytokine therapies, BCG-mediated immune activation, and novel intravesical delivery platforms.
Request a Custom Quote for MB49 Syngeneic ModelBiological and Molecular Characteristics
The MB49 cell line was established from a carcinogen-induced transitional cell carcinoma of the bladder in a C57BL/6 mouse. The tumor cells exhibit epithelial morphology, form cohesive clusters, and express urothelial markers such as cytokeratin and uroplakin. MB49 tumors display activation of oncogenic signaling pathways including EGFR, PI3K-AKT, and MAPK, contributing to their proliferative and invasive phenotype.
The tumor microenvironment is characterized by a high degree of immune infiltration, including macrophages, neutrophils, and lymphocytes, along with immunosuppressive elements such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). MB49 cells express PD-L1 and secrete cytokines such as IL-6 and TGF-beta, reflecting a dynamic immune interaction that parallels human bladder cancer. These properties make the MB49 model particularly suitable for preclinical immunotherapy research and intravesical treatment development.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Chemically induced urothelial carcinoma (mouse) |
| Histological type | Transitional cell carcinoma (urothelial carcinoma) |
| Inoculation route | Subcutaneous, intravesical (orthotopic), or intraperitoneal |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–6 days in vivo |
| Metastatic potential | Low in subcutaneous; local invasion in orthotopic models |
| Immunophenotype | Cytokeratin⁺, Uroplakin⁺, PD-L1⁺, EGFR⁺ |
| Common applications | Immunotherapy, BCG therapy, intravesical drug delivery, checkpoint blockade studies |
In Vivo Model Development and Tumorigenicity
The MB49 model can be established via subcutaneous or orthotopic implantation. Subcutaneous inoculation produces solid tumors suitable for efficacy testing and immune monitoring, while intravesical instillation following mild bladder wall injury generates orthotopic bladder tumors that closely simulate the pathogenesis of human urothelial carcinoma. Tumor establishment occurs within 5–7 days, with progressive local invasion of the bladder wall observed in orthotopic models.
The orthotopic MB49 model is particularly useful for investigating immunomodulatory therapies that rely on local immune activation, such as BCG and immune checkpoint inhibitors. Because of its immunocompetent host background and predictable progression, MB49 supports comprehensive evaluation of tumor–immune interactions, cytokine profiles, and response dynamics under physiologically relevant conditions.
Request a Custom Quote for MB49 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of MB49 tumors reveals solid nests and cords of epithelial tumor cells with prominent nucleoli, high nuclear-to-cytoplasmic ratios, and frequent mitotic figures. The tumors display areas of necrosis and hemorrhage surrounded by inflammatory infiltrates and fibrovascular stroma. In the orthotopic form, MB49 tumors exhibit progressive invasion of the bladder wall, muscularis propria, and, in advanced stages, perivesical tissue.
Immunohistochemical staining demonstrates strong expression of cytokeratin and uroplakin, confirming urothelial differentiation. Ki-67 staining indicates high proliferative activity, and CD31 highlights angiogenesis within the tumor stroma. PD-L1 expression is moderate to high and can be further upregulated following interferon exposure or checkpoint inhibitor treatment. F4/80 and CD11b staining identify macrophage and myeloid cell infiltration, while CD3 and CD8 highlight T-cell presence primarily at the tumor periphery. These histological and immunological characteristics faithfully replicate the architecture and immune landscape of human bladder carcinoma.
Preclinical Applications and Drug Response
The MB49 syngeneic model is a cornerstone in bladder cancer immuno-oncology. It has been extensively used to study immune checkpoint inhibitors, intravesical BCG therapy, cytokine adjuvants, and combinations with chemotherapeutic agents. The model is responsive to PD-1 and CTLA-4 blockade when combined with immunostimulatory treatments, making it a preferred system for mechanistic and translational studies.
MB49 is also utilized in the evaluation of nanoparticle-based drug delivery systems, oncolytic viruses, and radiation–immunotherapy combinations. The orthotopic variant is particularly valuable for studying immune infiltration, tumor regression, and local immune activation within the bladder microenvironment. Because of its reproducibility, well-characterized immune interactions, and translational relevance, MB49 remains the benchmark syngeneic model for preclinical bladder cancer research.
Request This Model
To request the MB49 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for MB49 Syngeneic Model